Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the beginning of the phase III trials of clascoterone solution in males for the treatment of androgenetic alopecia (AGA).
- The phase III trials will evaluate and assess the use of clascoterone topical solution in males
- AGA is the most common form of hair loss and a substantial market with high unmet needs. It is an extremely common disorder that affects roughly 50% of men
- Clascoterone topical solution is a potential first new mechanism of action in AGA in nearly three decades